Abstract:Biological molecules are increasingly becoming a part of the therapeutics portfolio that has been either recently approved for marketing or those that are in the pipeline of several biotech and pharmaceutical companies. This is largely based on their ability to be highly specific relative to small molecules. However, by virtue of being a large protein, and having a complex structure with structural variability arising from production using recombinant gene technology in cell lines, such therapeutics run the risk of being recognized as foreign by a host immune system. In the context of immune-mediated adverse effects that have been documented to biological drugs thus far, including infusion reactions, and the evolving therapeutic platforms in the pipeline that engineer different functional modules in a biotherapeutic, it is critical to understand the interplay of the adaptive and innate immune responses, the pathophysiology of immunogenicity to biological drugs in instances where there have been immune-mediated adverse clinical sequelae and address technical approaches for their laboratory evaluation. The current paradigm in immunogenicity evaluation has a tiered approach to the detection and characterization of anti-drug antibodies (ADAs) elicited in vivo to a biotherapeutic; alongside with the structural, biophysical, and molecular information of the therapeutic, these analytical assessments form the core of the immunogenicity risk assessment. However, many of the immune-mediated adverse effects attributed to ADAs require the formation of a drug/ADA immune complex (IC) intermediate that can have a variety of downstream effects. This review will focus on the activation of potential immunopathological pathways arising as a consequence of circulating as well as cell surface bound drug bearing ICs, risk factors that are intrinsic either to the therapeutic molecule or to the host that might predispose to IC-mediated effects, and review the recent literature on prevalence and intensity of established examples of type II and III hypersensitivity reactions that follow the administration of a biotherapeutic. Additionally, we propose methods for the study of immune parameters specific to the biology of ICs that could be of use in conjunction with the detection of ADAs in circulation.

Immune mediation of hypersensitivity adverse drug reactions: implications for therapy

Mechanisms of Unpredictable Adverse Drug Reactions

Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis

Non-IgE-Mediated Drug Hypersensitivity Reactions

Hydrogel-based approaches to target hypersensitivity mechanisms underlying autoimmune disease

Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic

The abscopal effect: Implications for drug discovery in autoimmunity

International Consensus on drug allergy

The Evolution of Therapeutic Immunosuppression and the Potential Impact of Drug Concentration Monitoring

Model Based Evaluation of Hypersensitivity Adverse Drug Reactions to Antimicrobial Agents in Children

Immune Checkpoints as Therapeutic Targets in Autoimmunity

Non-IgE-mediated drug-induced hypersensitivity reactions in pediatrics

Clues of HLAs, metabolic SNPs, and epigenetic factors in T cell-mediated drug hypersensitivity reactions

Changing patterns in the epidemiology of drug allergy

Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes

Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events

Immune-mediated inflammatory disease therapeutics: past, present and future

Variability of the Genes Involved in the Cellular Redox Status and Their Implication in Drug Hypersensitivity Reactions

Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire

Herb–Drug, Food–Drug, Nutrient–Drug, and Drug–Drug Interactions: Mechanisms Involved and Their Medical Implications

Role of allergen immunotherapy and biologics in allergic diseases